Quanterix Corporation

Equities

QTRX

US74766Q1013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
15.58 ^USD	+0.13%		-3.23%	-43.01%

Apr. 29	Canaccord Genuity Adjusts Price Target on Quanterix to $25 From $32, Maintains Buy Rating	MT
Apr. 12	Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election	CI

Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election

April 12, 2024 at 05:00 pm EDT

On April 8, 2024, Quanterix Corporation received notice from director Laurie Olson that she will not stand for re-election at the Company?s 2024 Annual Meeting of Stockholders, which is expected to be held on June 3, 2024.

Latest news about Quanterix Corporation

Canaccord Genuity Adjusts Price Target on Quanterix to $25 From $32, Maintains Buy Rating	Apr. 29	MT
Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election	Apr. 12	CI
Transcript : Quanterix Corporation - Special Call	Mar. 25
Scotiabank Raises Price Target on Quanterix to $32 From $30, Keeps Sector Outperform Rating	Mar. 04	MT
Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer?s Disease	Mar. 04	CI
Quanterix Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : Quanterix Corporation, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Quanterix Corporation Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Quanterix Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q4 Revenue $31.5M, vs. Street Est of $29.8M	Feb. 29	MT
Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023	Feb. 26	CI
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer?S Disease	Feb. 26	CI
Transcript : Quanterix Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	Jan. 10
Transcript : Quanterix Corporation, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $31.3M, vs. Street Est of $27.6M	Nov. 06	MT
Quanterix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $31.3M, vs. Street Est of $27.6M	Nov. 06	MT
Quanterix Corporation Revises Earnings Guidance for the 2023	Nov. 06	CI
Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease	23-10-24	CI
Quanterix Signs License Deal for Johnson & Johnson's p-Tau 217 Antibodies, Assay Designs	23-10-24	MT
Blood tests needed for widespread Alzheimer's diagnosis on the way	23-10-11	RE
Transcript : Quanterix Corporation Presents at Goldman Sachs Alzheimer?s Disease Day, Oct-03-2023 12:15 PM	23-10-03
Goldman Sachs Raises Price Target on Quanterix to $34 From $30, Maintains Buy Rating	23-09-27	MT
North American Morning Briefing : Yield Surge -2-	23-09-26	DJ
Canaccord Genuity Upgrades Quanterix to Buy From Hold, Raises Price Target to $32 From $25	23-09-25	MT

Chart Quanterix Corporation

Duration

Period

More charts

Company Profile

Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Quanterix Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.56 USD

Average target price

28.4 USD

Spread / Average Target

+82.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
QUANTERIX CORPORATION	-43.01%	595M
THERMO FISHER SCIENTIFIC	+8.69%	219B
DANAHER CORPORATION	+6.69%	183B
INTUITIVE SURGICAL, INC.	+10.90%	133B
BOSTON SCIENTIFIC CORPORATION	+25.41%	108B
SIEMENS HEALTHINEERS AG	+0.27%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+12.72%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	48.2B
AGILENT TECHNOLOGIES, INC.	+0.40%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+15.03%	39.35B

Other Advanced Medical Equipment & Technology